Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 2/2016

Open Access 01-02-2016 | Current Opinion

Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO

Authors: Karel Pavelka, Olivier Bruyère, Cyrus Cooper, John A. Kanis, Burkhard F. Leeb, Emmanuel Maheu, Johanne Martel-Pelletier, Jordi Monfort, Jean-Pierre Pelletier, René Rizzoli, Jean-Yves Reginster

Published in: Drugs & Aging | Issue 2/2016

Login to get access

Abstract

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA. Based on a literature review of clinical trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol. Additionally, diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped. The use of diacerein is associated with common gastrointestinal disorders such as soft stools and diarrhoea, common mild skin reactions, and, uncommonly, hepatobiliary disorders. However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions. Therefore, the ESCEO concludes that the benefit–risk balance of diacerein remains positive in the symptomatic treatment of hip and knee osteoarthritis. Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated.
Literature
1.
Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014;10(7):437–41.PubMed
2.
Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145–55.CrossRefPubMedPubMedCentral
3.
4.
Pelletier JP, Martel-Pelletier J. Therapeutic targets in osteoarthritis: from today to tomorrow with new imaging technology. Ann Rheum Dis. 2003;62 (Suppl 2):ii79–ii82.
5.
McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil. 2014;22:363–88 (Comment in: Osteoarthr Cartil. 2014;22(6):888–9; author’s reply 890–1; Corrigendum in: Osteoarthr Cartil. 2015;23(6):1026–34).
6.
Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil. 2010;18(4):476–99.CrossRefPubMed
7.
National Institute for Health and Clinical Excellence (NHS). Osteoarthritis: the care and management of osteoarthritis in adults. In: NICE clinical guideline 59. 2008. http://​www.​nice.​org.​uk/​CG059. Accessed 1 Feb 2013.
8.
Bruyere O, Cooper C, Pelletier JP, Branco J, Luisa Brandi M, Guillemin F, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44(3):253–63.CrossRefPubMed
9.
Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010;2(2):95–104.CrossRefPubMedPubMedCentral
10.
Moldovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, Martel-Pelletier J. Diacerhein and rhein reduce the ICE-induced IL-1 beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthr Cartil. 2000;8:186–96.CrossRefPubMed
11.
Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol. 1998;25(4):753–62.PubMed
12.
Pelletier JP, Mineau F, Ranger P, Tardif G, Martel-Pelletier J. The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthr Cartil. 1996;4(1):77–84.CrossRefPubMed
13.
Yaron M, Shirazi I, Yaron I. Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthr Cartil. 1999;7(3):272–80.CrossRefPubMed
14.
Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336(15):1066–71.CrossRefPubMed
15.
Martin G, Bogdanowicz P, Domagala F, Ficheux H, Pujol JP. Rhein inhibits interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation. 2003;27(4):233–46.CrossRefPubMed
16.
Ferreira Mendes A, Caramona MM, de Carvalho AP, Lopes MC. Diacerhein and rhein prevent interleukin-1 beta-induced nuclear factor-kappa B activation by inhibiting the degradation of inhibitor kappa B-alpha. Pharmacol Toxicol. 2002;91(1):22–8.
17.
Mathieu P. L’interleukine 1: son role, son dosage, ses difficultés d’approche dans l’arthrose. Résultats d’une étude ‘pilote ‘ avec la diacerhéine (ART 50) dans la gonarthrose [Interleukin 1 its role, quantitative determination and the difficulties in studying its role in osteoarthritis. Results of a ‘pilot’ study with diacerein (ART 50) in knee osteoarthritis]. Rev Prat. 1999;49(Suppl 13):S15–8. French.
18.
Felisaz N, Boumediene K, Ghayor C, Herrouin JF, Bogdanowicz P, Galerra P, et al. Stimulating effect of diacerein on TGF beta 1 and beta 2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthr Cartil. 1999;7(3):255–64.CrossRefPubMed
19.
Sanchez C, Mathy-Hartert M, Deberg MA, Ficheux H, Reginster JY, Henrotin YE. Effects of rhein on human articular chondrocytes in alginate beads. Biochem Pharmacol. 2003;65(3):377–88.CrossRefPubMed
20.
Schöngen RN, Giannetti BM, Van de Leur E, Reinards R, Greiling H. Effect of diacetylrhein on the phagocytosis of polymorphonuclear leucocytes and its influence on the biosynthesis of hyaluronate in synovial cells. Arzneimittelforschung. 1988;38(I)(5):744–8.
21.
Pelletier JP, Lajeunesse D, Reboul P, Mineau F, Fernandes JC, Sabouret P, et al. Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone. J Rheumatol. 2001;28(4):814–24.PubMed
22.
Legendre F, Bogdanowicz P, Martin G, Domagala F, Leclercq S, Pujol JP, et al. Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK-AP-1 dependent pathways. Clin Exp Rheumatol. 2007;25(4):546–55.PubMed
23.
Pelletier JP, Mineau F, Fernandes JC, Duval N, Martel-Pelletier J. Diacerhein and rhein reduce the interleukin 1 beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol. 1998;25(12):2417–24.PubMed
24.
Martel-Pelletier J, Mineau F, Caron J, Pelletier JP. Effect of diacerein/rhein on the Wnt system in human osteoarthritic subchondral bone [abstract]. Ann Rheum Dis. 2011;70(Suppl 3):354 (Abstract no. FRI0025).
25.
Boileau C, Tat SK, Pelletier JP, Cheng S, Martel-Pelletier J. Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther. 2008;10(3):R71.CrossRefPubMedPubMedCentral
26.
Brandt KD, Smith G, Kang SY, Myers S, O’Connor B, Albrecht M. Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthr Cartil. 1997;5:438–49.CrossRefPubMed
27.
Smith GN Jr, Myers SL, Brandt KD, Mickler EA, Albrecht ME. Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis Rheum. 1999;42(3):545–54.CrossRefPubMed
28.
Ghosh P, Xu A, Hwa SY, Burkhardt D, Little C. Evaluation des effets de la diacerhéine dans un modele ovin d’arthrose [Evaluation of the effects of diacerhein in an ovine model of osteoarthritis]. Rev Prat. 1998;48(Suppl 17):S24–30. French.
29.
Bendele AM, Bendele RA, Hulman JF, Swann BP. Effets bénéfiques d’un traitement par la diacerhéine chez des cobayes atteints d’arthrose [The beneficial effects of diacerein treatment in a guinea pig model of osteoarthritis]. Rev Prat. 1996;46:S35–9. French.PubMed
30.
Mazieres B, Berda L. Effect of diacerheine (ART 50) on an experimental post-contusive model of OA. Osteoarthr Cartil. 1993;1(1):47.
31.
Kitadai HK, Takahashi HK, Straus AH, Ibanez JF, Lucas R, Kitadai FT, et al. Effect of oral diacerein (DAR) in an experimental hip chondrolysis model. J Orthop Res. 2006;24(6):1240–8.CrossRefPubMed
32.
de Rezende MU, de Campos Gurgel HM, Vilaca Junior PR, Kuroba RK, Lopes AS, Phillipi RZ, et al. Diacerhein versus glucosamine in a rat model of osteoarthritis. Clinics. 2006;61(5):461–6.CrossRefPubMed
33.
Marcolongo R, Fioravanti A, Adami S, Tozzi E, Mian M, Zampieri A. Efficacy and tolerability of Diacerhein in the treatment of osteoarthrosis. Curr Ther Res. 1988;43(5):878–87.
34.
Nguyen M, Dougados M, Berdah L, Amor B. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum. 1994;37(4):529–36.CrossRefPubMed
35.
Delcambre B, Taccoen A. Etude d’ART 50 en pratique rhumatologique quotidienne [Study of ART 50 in daily rheumatological practice]. Rev Prat. 1996;46(6 Spec No):S49–S52. French.
36.
Fagnani F, Bouvenot G, Valat JP, Bardin T, Berdah L, Lafuma A, et al. Medico-economic analysis of diacerein with or without standard therapy in the treatment of osteoarthritis. Pharmacoeconomics. 1998;13(1 Pt 2):135–46.CrossRefPubMed
37.
Lequesne M, Berdah L, Gérentes I. Efficacité et tolérance de la diacerhéine dans le traitement de la gonarthrose et de la coxarthrose [Efficacy and tolerance of diacerhein in the treatment of gonarthrosis and coxarthrosis]. Rev Prat. 1998;48(Suppl 17):S31–5. French.
38.
Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine. 2000;7(3):177–83.CrossRefPubMed
39.
Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43(10):2339–48.CrossRefPubMed
40.
Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum. 2001;44(11):2539–47.CrossRefPubMed
41.
Pham T, Le Henanff A, Ravaud P, Dieppe P, Paolozzi L, Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis. 2004;63(12):1611–7.CrossRefPubMedPubMedCentral
42.
Jayaram S, Shetty N, Krishnamurthy V, Sharma VD, Naik MN, Apsangikar PD. Clinical study of the efficacy and tolerability of diacerein in the treatment of mild to moderate osteoarthritis: a randomized, multicentre, comparative study. Indian Pract. 2005;58(11):683–91.
43.
Zheng WJ, Tang FL, Li J, Zhang FC, Li ZG, Su Y, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a randomized, multicenter, double-dummy, diclofenac-controlled trial in China. APLAR J Rheumatol. 2006;9(1):64–9.CrossRef
44.
Pavelka K, Trc T, Karpas K, Vitek P, Sedlackova M, Vlasakova V, et al. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. Arthritis Rheum. 2007;56(12):4055–64.CrossRefPubMed
45.
Louthrenoo W, Nilganuwong S, Aksaranugraha S, Asavatanabodee P, Saengnipanthkul S, The Thai Study Group. The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthr Cartil. 2007;15(6):605–14.CrossRefPubMed
46.
Sharma A, Rathod R, Baliga VP. An open prospective study on postmarketing evaluation of the efficacy and tolerability of diacerein in osteo-arthritis of the knee (DOK). J Indian Med Assoc. 2008;106(1):54–6, 58.
47.
Brahmachari B, Chatterjee S, Ghosh A. Efficacy and safety of diacerein in early knee osteoarthritis: a randomized placebo-controlled trial. Clin Rheumatol. 2009;28(10):1193–8.CrossRefPubMed
48.
Singh K, Sharma R, Rai J. Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee. Int J Rheum Dis. 2012;15(1):69–77.CrossRefPubMed
49.
Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med. 2006;166(17):1899–906 (Erratum in: Arch Intern Med. 2007;167(5):444).
50.
Fidelix TS, Soares B, Fernandes Moca Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006;1:CD005117.
51.
Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moca Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014;2:CD005117.
52.
Bartels EM, Bliddal H, Schondorff PK, Altman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthr Cartil. 2010;18(3):289–96.CrossRefPubMed
53.
Mattara L. DAR: indagini “controllate” nel trattamento della osteoartosi [DAR “Controlled” studies in treatment of osteoarthrosis]. Paper presented at: Simposio Proter sulla diacereina. 86th Congresso Nazionale della Societa Italiana di Medicina Interna, 1985 Sep 24–27; Sorrento, Italy. Italian.
54.
Pietrogrande V, Leonardi M, Pacchioni C. Risultati della sperimentazione clinica in pazienti artrosici di un nuovo farmaco: la diacereina [Results of a clinical study with a new drug (Diacerein) in osteoarthritis patients]. Paper presented at: Simposio Proter sulla diacereina. 86th Congresso Nazionale della Societa Italiana di Medicina Interna, 1985 Sep 24–27; Sorrento, Italy. Italian.
55.
Fioravanti A, Marcolongo R. Efficacia terapeutica della Diacereina (DAR) nell’artrosi del ginocchio e dell’ anca [Therapeutic effectiveness of Diacerhein (DAR) in arthrosis of knee and hip]. Paper presented at: Toscana Medicina Symposium on Diacereina, Pisa, Italy. 1985 Oct 1. Italian.
56.
Mordini M, Nencioni C, Lavagni A, Camarri E. Diacereina VS naproxene nella coxo-gonoartrosi: studio randomizzato in doppio ciego [Diacerhein versus naproxen in coxo-gonarthrosis: double-blind randomized study]. Paper presented at: 27th Congresso Nazionale della Societa Italiana di Reumatologia, 1986 Oct 30–Nov 2; Montecatini, Italy. Italian.
57.
Mantia S. A controlled study of the efficacy and tolerability of Diacetylrhein in the functional manifestations of osteoarthritis of the hip and the knee. A double-blind study versus diclofenac [study report]. Palermo (Italy): Hospital of Palermo; 1987.
58.
Portioli I. A naproxen-controlled study on the efficacy and tolerability of diacetylrhein in the functional manifestations of osteoarthritis of the knee and hip. A double-blind study versus naproxen [study report]. Reggio Emilia (Italy): Hospital Santa Maria Nuova; 1987.
59.
Tang FL, Wu DH, Lu ZG, Huang F, Zhou YX. The efficacy and safety of diacerein in the treatment of painful knee osteoarthritis. Paper presented at: 11th Asia Pacific League of Associations for Rheumatology (APLAR) Congress, International Convention Center (ICC), 2004 Sep 11–15; Jeju, Korea.
60.
Ascherl R. Longterm treatment of osteoarthritis of the knee: a six months placebo-controlled clinical trial with diacerhein. Paper presented at: 2nd OARSI International Congress Symposium: Diacerhein and Interleukin 1 inhibition: a new therapeutical approach in osteoarthritis, 1995 Feb 4–5; Nice, France.
61.
Schulitz KP. Clinical investigation of the efficacy and tolerance of Diacetylrhein (DAR) in the treatment of osteoarthritis of the knee [study report]. Cologne (Germany): Madaus AG; 1994 Oct 27. 468 p. Report No. R-DA139.
62.
Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum. 2001;44(8):1736–43.CrossRefPubMed
63.
64.
Renan X, Lepage M, Connan D, Carlhant D, Riche C, Verger P, et al. Cas clinique d’une hépatite fatale a la diacerhéine [Case report of fatal hepatitis from diacerein]. Thérapie. 2001;56(2):190–1. French (Comment in: Thérapie. 2001;56:637–638).
65.
Mattei E, Marzoli GA, Oberto G, Brunetti MM. Diacerein effects on the cardiovascular function of the conscious dog following repeated oral administration [study report]. Rome (Italy): RTC Research Toxicology Centre; 2009. 81 p. RTC Study No. 70600.
66.
Middel B, van Sonderen E. Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research. Int J Integr Care. 2002;2:e15.CrossRefPubMedPubMedCentral
67.
Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008;67(12):1716–23 (Comment in: Minerva. 2009;8(9):117).
68.
Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging. 1998;13(3):245–53.CrossRefPubMed
69.
Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364–72.CrossRefPubMed
70.
71.
Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013;36(2):135–44.CrossRefPubMedPubMedCentral
72.
Rahme E, Barkun A, Nedjar H, Gaugris S, Watson D. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol. 2008;103(4):872–82.CrossRefPubMed
73.
Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79 (Comment in: Lancet. 2013; 382(9894): 746–748).
74.
Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S–24S.CrossRefPubMed
75.
Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881–9.CrossRefPubMed
76.
77.
Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2015.
78.
Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev. 2000;53:357–79.
79.
80.
Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021–9.CrossRefPubMed
81.
Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113(12):1578–87.CrossRefPubMed
82.
McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):1–18.CrossRef
83.
Walker AM. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1997;40(2):201–8.CrossRefPubMed
84.
Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs)—classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy. 2011;66(7):818–29.CrossRefPubMed
85.
Sanmarkan AD, Sori T, Thappa DM, Jaisankar TJ. Retrospective analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis over a period of 10 years. Indian J Dermatol. 2011;56(1):25–9.CrossRefPubMedPubMedCentral
86.
Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160(6):777–84.CrossRefPubMed
87.
Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–8.CrossRefPubMedPubMedCentral
88.
Panova E, Jones G. Benefit-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf. 2015;38:245–52.CrossRefPubMed
89.
Bruyere O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, et al. Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drugs Aging. 2015;32(3):179–87.CrossRefPubMedPubMedCentral
Metadata
Title
Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
Authors
Karel Pavelka
Olivier Bruyère
Cyrus Cooper
John A. Kanis
Burkhard F. Leeb
Emmanuel Maheu
Johanne Martel-Pelletier
Jordi Monfort
Jean-Pierre Pelletier
René Rizzoli
Jean-Yves Reginster
Publication date
01-02-2016
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 2/2016
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-016-0347-4

Other articles of this Issue 2/2016

Drugs & Aging 2/2016 Go to the issue

Therapy in Practice

Infection in Venous Leg Ulcers: Considerations for Optimal Management in the Elderly

Original Research Article

The Effect of Sleep Medication Use and Poor Sleep Quality on Risk of Falls in Community-Dwelling Older Adults in the US: A Prospective Cohort Study

Letter to the Editor

Comment on: Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects

Short Communication

Effects of Age on Glycemic Control in Patients With Type 2 Diabetes Treated with Insulin Detemir: A Post-Hoc Analysis of the PREDICTIVE™ 303 Study

Review Article

Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs

Systematic Review

Intra-Articular Therapies in the Treatment of Hand Osteoarthritis: A Systematic Literature Review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits